Found 19 Multiple Sclerosis trials
A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study will test the experimental drug, ZEN003694, in combination with a marketed drug, talazoparib (Talzenna®), in patients with triple negative breast cancer (TNBC). Among the questions it will seek to answer are: 1. What are well-tolerated doses of ZEN003694 and talazoparib that can be given together without causing significant …
The study is an open-label, randomized, parallel group study conducted in patients with histologically confirmed MPM of epithelioid or biphasic (predominantly [50%] epithelioid) histology who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum …
The purpose of the study is to determine the safety and tolerability of ATA188 in subjects with progressive forms of multiple sclerosis. Up to 42 male or female subjects with progressive forms of MS and 42 subjects with Relapsing-Remitting MS will be enrolled. The subjects will be randomized to receive …
NARCRMS is a national database that collects patient and physician-based information on MS and will bring together information and data collected in multiple registries and databases across the U.S. and Canada. We expect that data collected consistently over long periods of time, when carefully studied, will 1) produce new clues …
This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these …
Elevations in plasma levels of branched chain amino acids (BCAAs, comprising leucine, valine, and isoleucine), a large component of protein, are strongly associated with insulin resistance and type 2 diabetes, but mechanisms for this relationship are unclear. This protocol will determine whether excess BCAAs worsen free fatty acid-induced insulin resistance. …
This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
WIRB will be the Main IRB and Penn will be the relying IRB. NYHA Class I-II patients are now eligible for CRT following the MADIT CRT study, and there are no prior data for these patients using the SmartDelay feature. Furthermore, in the intervening seven years since the SMART AV …
11 - 19 of 19
- 1
- 2
